Trials / Terminated
TerminatedNCT03668405
A Study to Evaluate the Long-term Safety and Tolerability of Lu AF20513 and the Antibody Response in Patients With Alzheimer's Disease (AD)
Interventional, Open-label, Multiple-immunization Extension Study on the Safety, Tolerability and Immunogenicity of Lu AF20513/Adjuvant in Patients With Alzheimer's Disease
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 18 (actual)
- Sponsor
- H. Lundbeck A/S · Industry
- Sex
- All
- Age
- 60 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the long-term safety, tolerability and antibody response of Lu AF20513 in patients with Alzheimer's disease who have completed the 16026A study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lu AF20513 | Injection |
Timeline
- Start date
- 2018-06-26
- Primary completion
- 2019-05-27
- Completion
- 2019-05-27
- First posted
- 2018-09-12
- Last updated
- 2019-11-21
Locations
4 sites across 2 countries: Finland, Sweden
Source: ClinicalTrials.gov record NCT03668405. Inclusion in this directory is not an endorsement.